The Product Is Regulated. You Might Not Be.
Ask a room of injectors whether dermal filler is regulated in Europe and everyone says yes. Ask what that regulation requires of them and the answers scatter, because the question conceals three different ones.
Whether a product may lawfully be placed on the European market. Whether you may lawfully put it into a patient. And whether anybody is obliged to tell an authority when it goes wrong. European law answers the first at length, says almost nothing about the second, and puts the third mainly on someone who was not in the room.
Fillers and lasers are devices, even without a medical purpose
The Medical Devices Regulation applies to medical devices and, separately, to a listed set of products that have no intended medical purpose at all. That annex covers "substances, combinations of substances, or items intended to be used for facial or other dermal or mucous membrane filling by subcutaneous, submucous or intradermal injection or other introduction, excluding those for tattooing" — and, in its own group, "high intensity electromagnetic radiation … emitting equipment intended for use on the human body … such as lasers and intense pulsed light equipment, for skin resurfacing, tattoo or hair removal or other skin treatment" [1].
So a filler placed purely for appearance, and the laser used purely for appearance, are inside the device regime notwithstanding that neither treats a disease. The binding detail arrived later: common specifications for exactly those groups were laid down in a Commission implementing regulation, applying from 22 June 2023 [2]. This is settled law, not a forthcoming proposal — though transitional provisions, extended in 2023, still allow products lawfully marketed before that date to remain on sale for some years yet [2]. A product on the shelf today has not necessarily been assessed against the common specifications.
Toxin is not in that regime at all
Botulinum toxin sits under medicines law rather than device law, because it works by pharmacological action on the body — the definition that makes something a medicinal product under the European code [3]. That single difference is why the two treatments a practitioner offers on the same afternoon are governed by two unrelated systems, with different rules about supply, prescription and advertising.
It also explains something practitioners find arbitrary. Who may obtain the product still varies nationally, but advertising does not: EU law requires every member state to prohibit advertising prescription-only medicines to the general public [3], and botulinum toxin is prescription-only. Filler, being a device, has no equivalent EU-wide advertising prohibition. The reason is not that toxin is more dangerous. It is that one is a medicine and the other is a device.
Who may inject is not a European question
Here is where the assumption breaks, though not quite where people expect. The Regulation does not license practitioners, and it says so itself: it "shall not affect national law concerning the organisation, delivery or financing of health services and medical care, such as … the requirement that only certain health professionals or healthcare institutions may dispense or use certain devices" [1].
But the device regime is not silent either. Since 22 June 2023 the common specifications require every dermal filler in the EU to carry, on the label and at the head of the instructions for use in the largest bold type used, the statement that it is "Only to be administered by appropriately trained healthcare professionals who are qualified or accredited in accordance with national law" — together with a clear indication that it is not to be used in anyone under 18 [2].
Notice where that sentence lands. It sets an EU-level expectation that a healthcare professional administers the product, and then hands the definition of "qualified or accredited" straight back to your country. Scope of practice — whether a nurse, a dentist, a beautician or nobody but a physician may inject — remains national law, and it differs sharply across the internal market.
A Finnish registry-based study makes the gap concrete. Its authors note that Finnish legislation does not mandate healthcare training for those performing dermal filler treatments. In the 25 complaints they examined — the entire national set for the eight years to the end of 2024 — 56 per cent concerned treatments given in beauty salons. The practitioner was a beauty salon employee in 11 cases and a registered nurse in 6; in a further 6 the practitioner could not be identified from the records, and 2 complaints concerned a medical doctor [4].
Read that carefully, because it is a small study doing a large job. Twenty-five complaints to Finnish regulatory authorities over eight years is not an incidence rate and not a survey of European practice, and a quarter of the cases have no identified practitioner at all. It also cannot be read as a league table of who injects safely: the authors deliberately excluded the Patient Insurance Centre, which is where a complication caused by a healthcare professional would normally be handled, so the registries sampled systematically under-capture doctor- and nurse-performed cases.
What it does show, from official records rather than from anecdote, is that a product fully regulated at EU level was being injected in settings the same country's law did not require to have any healthcare training at all.
That is the entire point. Product regulation and practitioner regulation are separate questions, and the second one changes at every border.
The reporting duty is probably not yours
This surprises people. Under the Medical Devices Regulation, manufacturers must report serious incidents involving devices made available on the Union market to the competent authorities — with an exception for expected side-effects already documented in the product information and quantified in the technical file, which are handled by trend reporting instead. For healthcare professionals, users and patients, the Regulation requires Member States to "take appropriate measures such as organising targeted information campaigns, to encourage and enable" them to report suspected serious incidents [1].
Encourage and enable, not require. The binding EU-level obligation sits with the manufacturer; the practitioner's duty, where one exists, comes from national law. Several member states do impose one, so the answer where you practise may well be that you must report — but it will be your own country's rule that makes it so, not the Regulation.
None of this is a loophole to be indignant about. It is an allocation of duties that follows from what the Regulation is for. But it does mean that the safety picture assembled centrally is built substantially from what manufacturers submit, and a synthesis of the complications literature and media reporting concludes that complications from non-surgical aesthetic treatments remain underreported, inadequately studied and inconsistently regulated [5]. If reporting is voluntary for the person who saw what happened, that conclusion is not surprising.
What to do with this
Separate the three questions before you buy anything. Is this product lawfully on the market here — a question about CE marking and the manufacturer. May I administer it — a question for your national regulator or professional body. Must I report a complication — a question for national law, not the Regulation.
Do not read a CE mark as permission. It says the manufacturer has met the requirements for placing that product on the market. It says nothing about your qualification, your indication, or your patient.
Ask the scope-of-practice question before the course, not after. A training certificate records what you were taught. It does not grant an authorisation, and it does not travel across a border by itself — professional qualifications are recognised across the EU within a framework, but what a given professional may actually do remains national.
Report anyway. Where the duty is only to be encouraged and enabled, reporting is a professional choice rather than a legal one — and the underreporting problem above is made of those choices. A complication nobody hears about is one nobody can act on.
Why this belongs in a training decision
The commonest expensive mistake in this field is not clinical. It is a practitioner buying a course in one country, for a treatment that is lawful for their profession there, and discovering that at home the same treatment is reserved to someone else.
Nobody selling the course has an incentive to raise it, and the regulation everyone points at does not answer it. The question is short and belongs in the first email you send a training provider: not "is this product approved in Europe", which it almost certainly is, but "who is permitted to perform this where I practise, and what evidence will my regulator want that I was trained to do it".